Role of Cholinergic Signaling in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 139 of the 141 references it cites were found in a registry or an index.
Abstract
Acetylcholine, a neurotransmitter secreted by cholinergic neurons, is involved in signal transduction related to memory and learning ability. Alzheimer’s disease (AD), a progressive and commonly diagnosed neurodegenerative disease, is characterized by memory and cognitive decline and behavioral disorders. The pathogenesis of AD is complex and remains unclear, being affected by various factors. The cholinergic hypothesis is the earliest theory about the pathogenesis of AD. Cholinergic atrophy and cognitive decline are accelerated in age-related neurodegenerative diseases such as AD. In addition, abnormal central cholinergic changes can also induce abnormal phosphorylation of ttau protein, nerve cell inflammation, cell apoptosis, and other pathological phenomena, but the exact mechanism of action is still unclear. Due to the complex and unclear pathogenesis, effective methods to prevent and treat AD are unavailable, and research to explore novel therapeutic drugs is various and active in the world. This review summaries the role of cholinergic signaling and the correlation between the cholinergic signaling pathway with other risk factors in AD and provides the latest research about the efficient therapeutic drugs and treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second-generation AChEIs, including donepezil (4), rivastigmine (5), galantamine (6), are more selective. They exhibited fewer side effects or improved pharmacokinetic profiles, establishing them as first-line drugs for AD.98,400”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [98]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is a progressive neurodegenerative disorder and the leading cause of dementia among older adults, characterized by a gradual decline in cognitive function, memory loss, and behavioral changes, ultimately leading to complete dependence on caregivers [7].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these, neurons of the nucleus basalis of Meynert (NBM) are particularly vulnerable, and their degeneration leads to profound reductions in choline acetyltransferase (ChAT) activity within projection areas such as the cerebral cortex and hippocampus, regions essential for learning, memory, and attention [96].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This hypothesis suggests that a reduction in the synthesis and release of ACh impairs its physiological functions, which are critical for learning, memory, and other cognitive processes.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“The cholinergic hypothesis, one of the earliest and most influential theories of AD, proposed that the characteristic cognitive deficits of the disorder arise primarily from degeneration of cholinergic neurons in the basal forebrain [96].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [96]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Hafez, H. S., Ghareeb, D. A., Saleh, S. R., Abady, M. M., Demellawy, M. E., Hussien, H. M., & Abdel-Monem, N. M. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4690-x · Cited by 85
RetractedSemwal, B. C., & Garabadu, D. (2020) · NeuroMolecular Medicine · doi:10.1007/s12017-020-08615-1 · Cited by 9 · cited 2×
“Aβ can induce mitochondrial toxicity in the brain, resulting in cognitive dysfunction [5].”
BackgroundRetractedNEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311 · cited 1×
“According to clinical data in recent years, the brains of patients with AD show severe neurodegeneration and reduction of cholinergic neurons and a severe deficiency of Ach; acetylcholine transferase activity is significantly decreased, which further illustrates the damage to the cholinergic system in patients with AD…”
BackgroundEfficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.
Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Román, G. C., Jackson, R. E., Gadhia, R., Román, A. N., & Reis, J. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2019.08.005 · Cited by 421
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease
Osborn, L. M., Kamphuis, W., Wadman, W. J., & Hol, E. M. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.001 · Cited by 312 · cited 1×
“AD is a major cause of dementia which is a common disease among the elderly, starting with an irreversible decline in episodic memory and then a more general decline in overall cognitive ability [2,3].”
BackgroundLiu, Y., Zhang, Y., Zheng, X., Fang, T., Yang, X., Luo, X., Guo, A., Newell, K. A., Huang, X.-F., & Yu, Y. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1141-5 · Cited by 285 · cited 1×
“Liposaccharide (LPS) levels are higher in the brains of Alzheimer’s patients and are associated with neuroinflammation, which is controlled by neurocholinergic signaling, and cognitive decline [81,82].”
BackgroundLuo, H., Xiang, Y., Qu, X., Liu, H., Liu, C., Li, G., Han, L., & Qin, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00395 · Cited by 264 · cited 1×
“Liposaccharide (LPS) levels are higher in the brains of Alzheimer’s patients and are associated with neuroinflammation, which is controlled by neurocholinergic signaling, and cognitive decline [81,82].”
Background
Research works printed but not linked: 1
- Yu, 2019, Protective roles of isoastilbin against Alzheimer’s disease via Nrf2mediated antioxidation and antiapoptosis, Int. J. Mol. Med., 43, 1406
Cited by
Items 301–400 of 1,000
Dębiec, M., & Rojek, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062742 · Cited by 7
“Due to the multifactorial and complex pathogenesis of Alzheimer’s disease, effective methods for prevention and causal treatment remain currently unavailable, and intensive research into new therapeutic strategies is being conducted worldwide [55].”
Cognitive Effects of Almond Consumption: A Review of Animal Studies
Alami, K., Nazari, Z., Bayat, R., Bayat, A., Qasemi, S., Karimi, F., Sultani, M., & Mousavi, S. Y. (2024) · Nutrition and Dietary Supplements · doi:10.2147/nds.s469179 · Cited by 7
Bounaas, J., Basli, A., Mokrani, E. H., Ounissi, I., Benzazia, S., Özen, T., Sarmad, M., Erenler, R., Ilyas, Y., & Chawki, B. (2024) · Global NEST Journal · doi:10.30955/gnj.06823 · Cited by 7
Pradhan, S. P., Behera, A., & Sahu, P. K. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10170-0 · Cited by 7
Park, K., Lee, W. H., Cho, E., Kong, C. H., Min, H. S., Kim, M. S., Han, J. E., Jung, S. Y., Kim, D. H., & Ryu, J. H. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119500 · Cited by 7
Kuo, P., Chen, L., Li, S., Chen, Z.-R., & Chen, J. (2025) · Antioxidants · doi:10.3390/antiox14040413 · Cited by 7
Self-citationKumar, S., Bishnoi, P., Chauhan, N., Kumar, P., & Aggarwal, R. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2515812 · Cited by 7
Kotova, M. M., Stewart, A., Grigoryan, A., Shariff, S., Mirzaei, F., Kantawala, B., Dilbaryan, K., de Abreu, M. S., Galstryan, D. S., Cui, J., et al. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70090 · Cited by 8
“While AD is characterized by substantial neuronal loss predominantly in the hippocampus and cerebral cortex, its symptoms worsen with the progressive loss of cholinergic neurons critical for memory consolidation (Hampel et al. 2018; Ferreira-Vieira et al. 2016; Chen et al. 2022).”
Ferreira, F. D. S., de Mattos, J. L. A., da Silva, P. H. F., da Costa, C. A., Ognibene, D. T., Resende, Â. C., & de Bem, G. F. (2025) · Plants · doi:10.3390/plants14132010 · Cited by 7
“In AD, there is cholinergic dysregulation between the basal forebrain and its target tissues, such as the hippocampus, resulting from the neurodegeneration of neurons that synthesize acetylcholine and contributing to the development of memory deficits [99,100].”
Panda, H. S., Dhokne, M. D., Thakur, S., Singh, N. K., Datusalia, A. K., & Panda, J. J. (2025) · Small · doi:10.1002/smll.202411701 · Cited by 7
Medetalibeyoğlu, H., Tüzün, B., Atalay, A., Ortaakarsu, A. B., Sağlamtaş, R., Manap, S., Akyıldırım, O., & Yüksek, H. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143176 · Cited by 7
Kermaninia, S., Mohammadi‐Khanaposhtani, M., Khouzani, N. B., Dastyafteh, N., Moradkhani, F., Saeedi, S., Larijani, B., Dadgar, A., Aktaş, A., Sadeghian, N., et al. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143490 · Cited by 7
Gholami, M., Sarahroodi, S., & Abbasi-Maleki, S. (2025) · Phytomedicine Plus · doi:10.1016/j.phyplu.2025.100872 · Cited by 7
Khairinisa, M. A., Fakih, T. M., & Ramadhan, D. S. F. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110970 · Cited by 7
Decoding the neuroprotective potential of hesperidin: Insights into Alzheimer’s disease
Chauhan, P., Vadia, N., Ballal, S., Joshi, K. K., Maharana, L., Chauhan, A. S., Abomughaid, M. M., Lakhanpal, S., Avinash, D., Thakur, K., et al. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.09.028 · Cited by 7
MosGraphFlow: a novel integrative graph AI model mining signaling targets from multi-omic data
Zhang, H., Cao, D., Xu, T., Chen, E., Li, G., Chen, Y., Payne, P., Province, M. A., & Li, F. (2025) · BMC Methods · doi:10.1186/s44330-025-00041-8 · Cited by 7
Guarino, D., Carannante, I., & Destexhe, A. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013765 · Cited by 7
Structural similarity networks reveal brain vulnerability in dementia
Montagnese, M., Ebneabbasi, A., García-San-Martín, N., Pecci-Terroba, C., Romero-García, R., Morgan, S. E., Cole, J. H., Seidlitz, J., Rittman, T., & Bethlehem, R. A. I. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70973 · Cited by 7
“Neurotransmitters are especially relevant in the context of the MIND metric and AD because they not only shape large-scale inter-regional coupling 49,50 but are also highlighted in AD pathology (e.g., cholinergic and glutamatergic dysfunction 51–53 ).”
Aspartame consumption causes cognitive impairment in streptozotocin-induced diabetic Wistar rats
Ediga, M. G., Annapureddy, S., Salikineedy, K., & Nimgampalle, M. (2023) · Biologia · doi:10.1007/s11756-023-01363-0 · Cited by 7
“Int J Pediatr Obes 5:305–312 Buccellato FR, D’Anca M, Galimberti D et al (2021) Role of oxidative damage in Alzheimer’s disease and neurodegeneration: from pathogenic mechanisms to biomarker discovery.”
BackgroundInfluentialTyler, S. E. B., & Tyler, L. D. K. (2023) · Brain Disorders · doi:10.1016/j.dscb.2023.100094 · Cited by 7
Mihaylova, R., Angelova, V. T., Tchekalarova, J. D., Atanasova, D., Ivanova, P., & Simeonova, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115969 · Cited by 7
“Furthermore, several studies have demonstrated the in vivo anticholinergic effects of A β peptides administered directly into various brain structures without apparent immediate neurotoxicity [14,17–19].”
BackgroundMethodWeishaupt, A.-K., Ruecker, L., Meiners, T., Schwerdtle, T., Ávila, D. S., Aschner, M., & Bornhorst, J. (2024) · Toxicological Sciences · doi:10.1093/toxsci/kfae092 · Cited by 7
Alzheimer’s Disease Diagnosis and Management in the Age of Amyloid Monoclonal Antibodies
Hales, C. M. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.10.003 · Cited by 7
Thakur, A., Singh, R., Mehta, V., & Paliwal, D. (2025) · ChemistrySelect · doi:10.1002/slct.202500130 · Cited by 7
Prema, V., Meena, A., & Ramalakshmi, N. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249300784240430110628 · Cited by 6
Advances in design strategies and imaging applications of specific butyrylcholinesterase probes
Sun, T., Dong, Z., Malugulu, P. M., Zhen, T., Wang, L., Chen, Y., & Sun, H. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.110451 · Cited by 6
Irsal, R. A. P., Gholam, G. M., Dwicesaria, M. A., Mansyah, T. F., & Chairunisa, F. (2024) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2024.09.003 · Cited by 6
Shrivastava, P., Lu, Y., Su, S., Kobayashi, Y., Zhao, Y., Lien, N., Masoud, A., Lukiw, W. J., & Hong, S. (2024) · Biomedicines · doi:10.3390/biomedicines12122865 · Cited by 6
Negi, N., Ayyannan, S. R., & Tripathi, R. K. P. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03365-2 · Cited by 7
Ghosh, S., Das, B., Jana, S., Singh, K. O., Sharma, N., Mukherjee, P. K., & Haldar, P. K. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01535-8 · Cited by 6
“Abnormalities in cholinergic neurotransmission associated with AChE/BChE deficiency, neuro-inflammation, and oxidative stress (Chen et al. 2022; Greig et al. 2005).”
Teerapattarakan, N., Kamsrijai, U., Janyou, A., Hankittichai, P., Anukanon, S., Hawiset, T., & Issara, U. (2025) · South African Journal of Botany · doi:10.1016/j.sajb.2025.03.014 · Cited by 6
Pinheiro, R. F., Colón, D., & Fonseca-Pinto, R. (2025) · Neurocomputing · doi:10.1016/j.neucom.2025.129967 · Cited by 6
Romero‐Márquez, J. M., Navarro‐Hortal, M. D., Varela‐López, A., Calderón‐Iglesias, R., Puentes, J. G., Giampieri, F., Battino, M. A., Sánchez‐González, C., Xiao, J., García‐Ruiz, R., et al. (2025) · Food Frontiers · doi:10.1002/fft2.70013 · Cited by 6
Research progress of cell senescence in Alzheimer's disease: mechanisms and therapy
Cai, J., Yang, L. C., Xu, Y., Wang, L., Zhang, M., Qiao, J., Qian, X., Zhu, H., & Cai, M. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177697 · Cited by 6
Khoshnam, S. E., Sarkaki, A., Farbood, Y., Keshavarz, A., Dehcheshmeh, M. G., & Vastegani, S. M. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04417-8 · Cited by 6
Zhang, Y., Xu, Z., Zhu, J., Zhu, X., Zhao, J., & Liu, X. (2025) · Records of Natural Products · doi:10.25135/rnp.518.2501.3418 · Cited by 6
“Additionally, according to the cholinergic hypothesis [15], the low level of acetylcholine (ACh) in AD patients' brains hinders the signal transmission between synapses of nerve cells [16].”
Zhang, L., Ivleva, E. I., Parker, D., Hill, S. K., Lizano, P. L., Keefe, R. S. E., Keedy, S., McDowell, J. E., Pearlson, G. D., Clementz, B. A., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240709 · Cited by 6
Rao, J. S., Tangarife, M. A., Rodríguez‐Soacha, D. A., Arbelaez, M. J., Venegas, M. M., Delgado‐Murillo, L., Shahnawaz, S. S., Grimaldi, C., Gutiérrez, E., & Mukunda, R. (2025) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad2020015 · Cited by 6
Almazán, J. L., Cortes-Flores, E., Ramírez-Olvera, A., Palomero‐Rivero, M., Camacho‐Concha, N., Guerra‐Crespo, M., Prieto, G. A., Pérez‐Martínez, L., & Pedraza‐Alva, G. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.06.019 · Cited by 6
Waiwut, P., Takomthong, P., Anorach, R., Lomaboot, N., Daodee, S., Chulikhit, Y., Monthakantirat, O., Khamphukdee, C., & Boonyarat, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136287 · Cited by 6
Bhardwaj, B., Vishwakarma, S. K., Singh, A., Kumar, H., Gajendra, T. A., Verma, A., Krishnamurthy, S., Davisson, V. J., & Shrivastava, S. K. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118047 · Cited by 6
Recent Advances and Future Directions in Alzheimer’s Disease Genetic Research
Stancheva, M., Toncheva, D. I., & Karachanak-Yankova, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167819 · Cited by 6
“…brain, the nucleus basalis contains approximately 500,000 cholinergic neurons, whereas in advanced Alzheimer’s disease, this number may decline to just 100,000, undergoing extensive degeneration of over 75% [10], as these neurons experience selective loss, resulting in cholinergic deficiency [13].”
Redox reactivities of membrane-bound amyloid-β-Cu complexes and their targeting by metallothionein-3
Perez-Medina, L., & Meloni, G. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.08.047 · Cited by 6
Jayaprakash, P., Bhattacharyya, S., Saikia, H., Begum, T., & Lal, M. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108652 · Cited by 6
Meher, M. M., Afrin, M., Jahan, M. R., Nozaki, K., Masumoto, K., Yanai, A., & Islam, M. N. (2025) · Acta Histochemica · doi:10.1016/j.acthis.2025.152291 · Cited by 6
Sagpariya, T., Srivastava, N., Katiyar, S., & Choudhury, A. R. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148391 · Cited by 6
Bridging the gap in the management of Alzheimer's disease using fecal microbiota transplantation
Bashir, B., Gulati, M., Vishwas, S., Hussain, M. S., Gupta, G., Kumar, P., Negi, P., Mittal, N., Dua, K., & Singh, S. K. (2025) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2025.104052 · Cited by 6
Ali, S. H., Osmaniye, D., & Kaplancıklı, Z. A. (2025) · RSC Advances · doi:10.1039/d5ra05755h · Cited by 6
Cihan, C., Faydalı, N., Erol, M., Temiz‐Arpacı, Ö., Muhammed, M. T., & Dilek, E. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109281 · Cited by 6
Chudhary, M. (2025) · Chemical Papers · doi:10.1007/s11696-025-04532-4 · Cited by 6
Supasai, S., Suntaratti, P., Odton, M., Longji, T., Karananan, T., Yasom, S., Ampawong, S., Limpanont, Y., & Mutirangura, A. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115583 · Cited by 6
Shah, M., Patel, K., Kulkarni, U., Yadav, M. R., Patel, A., & Nagani, A. (2026) · Molecular Diversity · doi:10.1007/s11030-025-11458-2 · Cited by 6
Kasapoğlu, Ö. A., Çakıcı, A., Sağlamtaş, R., Salama, M., Asma, H. A. R. B., Sarıci, B., & Demir, Y. (2026) · ChemistrySelect · doi:10.1002/slct.202504774 · Cited by 6
Rai, H., Singh, R., Shankar, G., Rai, S., Kumar, P., Nilakhe, A., Singh, N., Bhadoria, P., Singh, G., Ramanathan, V., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68282-3 · Cited by 6
Khodaei, F., Namavar, M. R., Soutodeh, N., Hadipour, A., Asadi, F., Khoshnoud, M. J., & Rashedinia, M. (2026) · Scientific Reports · doi:10.1038/s41598-025-31867-5 · Cited by 6
Wal, P., Dutta, A., Jawaid, T., Rahman, M. U., Gowri, K., Jyothi, S. R., Kaur, I., Al-Hasnaawei, S., Sinha, A., Maharana, L., et al. (2026) · Biogerontology · doi:10.1007/s10522-026-10394-4 · Cited by 7
Omar, M. A., Al‐Ashmawy, A. A. K., Salam, H. A. A. E., El‐Shiekh, R. A., Aboulthana, W. M., & Srour, A. M. (2026) · Scientific Reports · doi:10.1038/s41598-026-39534-z · Cited by 6
Bridging the gaps in alzheimer’s disease: a comprehensive review of current and emerging therapies
Mostafa, R. E., & Asaad, G. F. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02151-3 · Cited by 6
“While they do not halt or reverse the underlying neurodegeneration, they remain a mainstay in clinical practice due to their modest but meaningful benefits in quality of life and daily functioning (Chen et al. 2022a, b).”
Şenol, H., Demir, Y., Tokalı, P., Şenol, A. M., Akyıldırım, O., & Tokalı, F. S. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110354 · Cited by 6
Inhibition of Cholinesterases by Benzothiazolone Derivatives
Alagöz, M. A., Kim, S., Oh, J., Arslan, G., Özdemir, Z., Sarı, S., Özçelik, A. B., Önkol, T., Trisciuzzi, D., Nicolotti, O., et al. (2022) · Processes · doi:10.3390/pr10091872 · Cited by 6
Abolhasani, F., Pourshojaei, Y., Mohammadi, F., Esmaeilpour, K., Asadipour, A., Ilaghi, M., & Shabani, M. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137332 · Cited by 6
Ge, Y., Ming, L., & Xu, D. (2024) · Neurological Research · doi:10.1080/01616412.2024.2338031 · Cited by 6
“Learning and memory consolidation are facilitated by cholinergic stimulation, whereas blocking cholinergic activity contributes to amnesia [14,15].”
BackgroundPhenylstyrylpyrimidine derivatives as potential multipotent therapeutics for Alzheimer's disease
Devi, B., Jangid, K., Kumar, V., Arora, T., Kumar, N., V, Dwivedi, A. R., Parkash, J., & Kumar, V. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00277f · Cited by 6
Alotaibi, B. S., Saleem, U., Farrukh, M., Waseem, S., Chauhdary, Z., Alsharif, I., Al-Qahtani, W. S., Alanzi, A. R., BinMowyna, M. N., Shah, M. A., et al. (2024) · Italian Journal of Food Science · doi:10.15586/ijfs.v36i3.2643 · Cited by 6
The Effect of Physical Exercise on Patients With Mild Cognitive Impairment: A Scoping Review
Stavrou, V. T., Vavougios, G. D., Hadjigeorgiou, G. M., & Bargiotas, P. (2024) · Cureus · doi:10.7759/cureus.73265 · Cited by 7
Gurumayum, N., Devi, M. B., Khound, P., Bhattacharya, A., Sarma, H., Khan, M. R., & Devi, R. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.11.016 · Cited by 6
Mohammadi, K., Eskandarpour, V., Nadri, H., Nejabat, M., & Hadizadeh, F. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.142451 · Cited by 6
Banoo, R., Nuthakki, V. K., Abdullaha, M., Sharma, M. R., & Bharate, S. B. (2022) · Drug Development Research · doi:10.1002/ddr.21997 · Cited by 6
“2022;83:1791–1802. wileyonlinelibrary.com/journal/ddr © 2022 Wiley Periodicals LLC. | 1791 levels (Z. R. Chen et al., 2022; Hampel et al., 2019).”
Putri, A. D. A., Sembiring, M. H., & Tuba, S. (2024) · Communicative & Integrative Biology · doi:10.1080/19420889.2024.2357346 · Cited by 6
“In Alzheimer’s patients, acetylcholine levels tend to be low; therefore, inhibiting this enzyme can increase acetylcholine levels in the brain and reduce cognitive symptoms [2].”
BackgroundLee, C. H., Ko, M. S., Kim, Y.-S., Ham, J. E., Choi, J. Y., Hwang, K. W., & Park, S. (2023) · Pharmaceuticals · doi:10.3390/ph16111606 · Cited by 6
“The filtrate was concentrated under vacuum to obtain 235.5 g of DME, which was subsequently utilized for further studies.”
MethodInfluentialAlzheimer ve Parkinson Hastalıklarında Bor İçeren Bileşiklerin Nörokoruyucu Etkisi
BİTMEZ, B., & Balbal, B. (2024) · Journal of Boron · doi:10.30728/boron.1408368 · Cited by 5
Haque, A., Alenezi, K. M., & Rasheed, M. S. M. A. (2024) · New Journal of Chemistry · doi:10.1039/d4nj02065k · Cited by 5
Mishra, M. A., Sahu, P. K., Satapathy, B. S., & Biswal, B. (2024) · Current Nanomaterials · doi:10.2174/0124054615322050240817172547 · Cited by 5
Saral, S., Mercantepe, T., Topçu, A., Kaya, A. K., & Öztürk, A. (2024) · Life · doi:10.3390/life14121672 · Cited by 5
“Cholinergic atrophy and cognitive decline are among the most important indicators in age-related neurodegenerative diseases such as AD [7].”
Al-Abbas, N. S., & Shaer, N. A. (2024) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823241309024 · Cited by 5
“51 The de fi ciency of ACh is a well-established pathological hallmark of AD, initially proposed as the cholinergic hypothesis.”
Atta, A. M., Elkalla, W. S., Omran, S. A., & Elgawish, M. S. (2025) · Egyptian Pharmaceutical Journal · doi:10.21608/epj.2025.407574 · Cited by 5
“Besides, the abnormal cholinergic alteration resulted in many pathological conditions like anomalous tau protein phosphorylation and apoptosis of nerve cells [4].”
InfluentialSchwarze‐Taufiq, T. A., Pranoto, I. K. A., Hui, K., Kinoshita, C., Yu, O., Crane, P. K., Gray, S. L., & Young, J. E. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70040 · Cited by 5
Wang, X., Zhang, Y., Muhire, J., Di, D., Huang, X., & Pei, D. (2025) · Separations · doi:10.3390/separations12040096 · Cited by 5
“These are mainly huperzine A, tacrine, and donepezil [5].”
Dar, N. A., Wani, O. H., Wang, Y., Khan, F. I., Ganie, B. A., Shah, S. W. A., Dar, T. A., & Ismail, T. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100289 · Cited by 5
Neuroprotective Potential of Broccoli Sprout Extract in Scopolamine-Induced Memory-Impaired Mice
Jeong, H., Choi, H.-J., & Park, Y. (2025) · Foods · doi:10.3390/foods14173059 · Cited by 5
“Hallmark pathological features include oxidative stress, neuroinflammation, and diminished levels of neurotrophic factors, particularly in the cortex and hippocampus [1].”
Boosting Neurogenesis as a Strategy in Treating Alzheimer’s Disease
Dwamena, A. A., Arachchi, R. Y. B., & Wang, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188926 · Cited by 5
“These behavioral effects were closely linked to neurogenesis: reducing ACh decreased the number of new neurons that survived and integrated into olfactory circuits, while increasing ACh activity enhanced their survival and integration [57,58].”
8-Hydroxyquinoline Derivatives as Drug Candidates for the Treatment of Alzheimer's Disease
Bartolomeu, P. F., Fortes, I. S., Zimmer, A. R., Lopes, M. S., & de Andrade, S. F. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673409645250823055140 · Cited by 5
Systematic review: Effects of cholinergic signaling on cognition in human pharmacological studies
Dan, Y. R., Christakou, A., & Roelofs, K. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106408 · Cited by 5
A Review on the Pathophysiology of Alzheimer’s Disease
Agarwal, U., Kapoor, G. T., & Tonk, R. K. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037416859250915091846 · Cited by 5
Bulut, Z., Karaküçük‐İyidoğan, A., Bilge, M., Sıcak, Y., Turgut‐Solak, Z. D., & Oruç‐Emre, E. E. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70124 · Cited by 5
“In this context, the discovery that cholinesterase enzymes play a role in the accumulation of β ‐ amyloid plaques, tau phosphorylation, and the formation of neurofibrillary tangles has increased the importance of these inhibitors [20 – 23].”
Sarup, P., Malik, J., & Pahuja, S. (2025) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2025.1004121 · Cited by 5
Dang, K., Zheng, Q., Zhou, T., Wang, Y., Pan, D., Du, L., Suo, S., Dang, Y., Ma, L., & Gao, X. (2025) · Food Chemistry · doi:10.1016/j.foodchem.2025.147028 · Cited by 5
Salminen, A. (2026) · Neurochemistry International · doi:10.1016/j.neuint.2026.106115 · Cited by 5
Cadaxo, A. S., Cotrin, J. C., Valente, A. P., Lopes, F. G., Veras, R. P., Torres, D. S., da Costa, R. Q. M., dos Santos, G. C., & Santos-Rebouças, C. B. (2026) · Brain Research · doi:10.1016/j.brainres.2026.150167 · Cited by 5
Ghosh, A., Bhakta, S., Kapse, N. G., Dhakephalkar, P. K., Patra, C., & Gorain, B. (2026) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2026.181443 · Cited by 5
Sharmah, H., Ahmed, L. A., Kemisetti, D., Kumar, S., Samanthula, K. S., Panigrahy, U. P., & Ghosh, N. S. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11503-8 · Cited by 5
Mitochondrial dysfunction in Alzheimer's disease and related sex differences
Misrani, A., Ngwa, C., & Liu, F. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1761702 · Cited by 6
“In AD, impaired cholinergic neurotransmission is a central contributor to deficits in memory and learning (Hampel et al., 2019; Chen Z. R. et al., 2022).”
Mishra, A., Satapathy, B. S., & Sahu, P. K. (2026) · Discover Nano · doi:10.1186/s11671-026-04528-3 · Cited by 5
Shajahan, S. R., Hamid, N., Okunsai, B., Shari, N. B., & Ramli, M. D. C. (2026) · Biomedicines · doi:10.3390/biomedicines14040860 · Cited by 5
“These molecules activate peripheral innate immune pathways through pattern recognition receptors, including Toll-like receptors (TLRs), driving sustained production of pro-inflammatory cytokines (e.g., IL-1 β , IL-6, TNF-α ) that amplify systemic inflammatory tone [27,28].”
El-Hema, H. S., Ahmed, A., Waheed, A., Hawata, M. A., Hussein, M. F., Khalifa, M. M., Elhendawy, A. T., El‐Sayed, H. A., & Abdel‐Rahman, A. A. ‐. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146452 · Cited by 5
Dastmalchi, N., & Hajiasgharzadeh, K. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153906 · Cited by 5
Petrov, W., Ślebioda, D., Kozińska, R. B., Kukla, K., Petrov, P., Sroka, M., Tesyna, J., Puźniak, G., Kudliński, M., Rejda, T., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135733 · Cited by 6
“Levels of ACh are maintained by choline acetyltransferase (ChAT) and AChE [12,13].”
Al‐Rifai, N., Al-Khalileh, N. M., Zahra, J. A., El‐Barghouthi, M. I., & Darras, F. H. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2281264 · Cited by 5
Chen, S., Liu, J., Luo, S., Xing, L., Li, W., & Gong, L. (2024) · Animals · doi:10.3390/ani14111547 · Cited by 5
Alzheimer’s disease and epilepsy: Research hotspots for comorbidity in the era of global aging
Zhou, X., Liu, Y., Wu, Z., Zhang, X., & Tao, H. (2024) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2024.109849 · Cited by 5
Metadata
- Authors
- Chen, Z.-R., Huang, J.-B., Yang, S.-L., & Hong, F.-F.
- Affiliations
- Nanchang University (CN)
- Experimental Center of Pathogen Biology, Nanchang University, Nanchang 330031, China
- Corresponding author
- Yang, Shu-Long
- Hong, Fen-Fang
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-03-10
- Volume
- 27
- Issue
- 6
- Pages
- 1816
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC8949236
- OpenAlex
- W4220945110
- Cited by
- 922
- References
- 141
- Citations by year
- 2026: 256 · 2025: 347 · 2024: 202 · 2023: 87 · 2022: 29
- FWCI
- 22.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (82060661, 81660751, 81660151)
- Jiangxi Provincial Natural Science Foundation of China (20212BAB206092)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cholinergic neurotransmission, acetylcholine, cholinergic hypothesis, cognitive decline, tau phosphorylation, neuroinflammation, apoptosis, Alzheimer's disease pathogenesis, Alzheimer's disease therapeutics
- MeSH terms
- Acetylcholine, Alzheimer Disease, Humans, Signal Transduction, Cholinergic Agents, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.